Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16097466 | 0.95 | LMNA (0.47) | GAAKDM4EPDK2LMNAPTGS2 | |
| SCHEMBL3927973 | 0.91 | GAA (0.53) | GAAKDM4ELMNAMAPK1PTGS2 | |
| SCHEMBL21225478 | 0.85 | ALDH1A1 (0.54) | GAAKDM4ELMNAHPGDKMT2A | |
| SCHEMBL7714080 | 0.85 | ALDH1A1 (0.44) | GAAKDM4ELMNAHPGDPOLB | |
| SCHEMBL16898154 | 0.83 | LMNA (0.41) | GAAKDM4EPDK2LMNAPTGS2 | |
| SCHEMBL16898159 | 0.82 | NOTUM (0.49) | GAAKDM4EPDK2LMNAPTGS2 | |
| SCHEMBL3146089 | 0.81 | PDK2 (0.48) | KDM4EPDK2LMNAMAPK1PTGS2 | |
| SCHEMBL14501365 | 0.79 | PPARG (0.46) | GAAKDM4EMAPK1PTGS2KMT2A | |
| SCHEMBL1571230 | 0.79 | PTGS2 (0.54) | GAAKDM4EPTGS2POLBKMT2A | |
| SCHEMBL18241197 | 0.79 | LMNA (0.38) | GAAKDM4EPDK2LMNAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | GAA 5/4885KDM4E 1736/4885PDK2 2440/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | GAA 5/4885KDM4E 1736/4885PDK2 2440/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | GAA 5/4885KDM4E 1736/4885PDK2 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.